- Oncolytics Biotech (ONCY, Financial) presents new data showing pelareorep's effectiveness in turning 'cold' tumors 'hot' in multiple cancer types.
- Data from GOBLET and AWARE-1 studies reveal significant immune system activation, improving treatment outcomes for resistant cancers.
- Anticipated updates on clinical timelines are expected by the end of Q3 2025.
Oncolytics Biotech Inc. (NASDAQ: ONCY), a leader in developing cancer immunotherapies, has released comprehensive translational data showcasing the efficacy of its candidate, pelareorep, across various tumor types. The data from the GOBLET and AWARE-1 studies highlight the oncolytic virus's ability to transform immunologically 'cold' tumors into 'hot' ones by upregulating immune markers like interferons and PD-L1, and increasing tumor-infiltrating lymphocytes. This transformation is crucial for enhancing the effectiveness of immunotherapies.
The promising results were particularly evident in challenging cancer types such as pancreatic, gastrointestinal, and breast cancers. The successful conversion of 'cold' tumors to 'hot' phenotypes indicates potential synergies with existing checkpoint inhibitors, offering hope for patients with historically resistant cancers.
Oncolytics plans to continue enrolling patients in the GOBLET study, specifically targeting pancreatic ductal adenocarcinoma and anal carcinoma. Additional translational data readouts are expected next year, with a clinical timeline update slated for release by the end of Q3 2025. These developments position pelareorep as a potential candidate for registration-enabling trials, paving the way for broader applications in the field of oncology.
